• By Kevin E. Noonan —

    Chinese FlagOn January 15th, the U.S. and China announced bilateral approval of an agreement resolving some of the trade disputes between the two countries that have developed (or become more evident) over the past three years.  One of the most consistent (if sometimes incoherently expressed) policy positions taken by the Trump Administration (and Mr. Trump himself) is that the trade balance between the U.S. and China has been unbalanced and in need of correction.  This idea is not unique to Mr. Trump (although its idée fixe nature may be) and has been a feature of the U.S. Trade Representative's Special 301 Report for the past decade (most recently last April).  It has been the source of numerous tariffs imposed on China by this Administration (even in the face of criticism from economists and others that U.S. consumers and farmers, not the Chinese, bore the brunt of the consequences and the costs) and the periodic imposition of these tariffs has rattled the financial markets since the time when Mr. Trump first came into office.

    US FlagRepresentatives from the U.S. and China announced, with much fanfare, the completion of the first round of what is envisioned (or purported) to be several agreements between the two countries, and released the text of the agreement that on its face looks favorable to U.S. interests but on further study may in fact not be.

    The Agreement has eight chapters and several articles for each chapter.  After reciting a Preamble containing the importance of a "bilateral economic and trade relationship" between the U.S. and China, and "adherence to international norms" to promote it, and acknowledging the "trade and investment concerns" identified by both countries and that it is desirable for the countries to resolve them, the Agreement in Chapter 1 immediately addresses Intellectual Property concerns.

    These begin with generic representations such as "[t]he Parties shall ensure fair, adequate, and effective protection and enforcement of intellectual property rights.  Each Party shall ensure fair and equitable market access to persons of the other Party that rely upon intellectual property protection" (Article 1.2) and then gets into specifics regarding Trade Secrets and Confidential Business Information (Article 1, Section B); Pharmaceutical-related Intellectual Property (Section C); Patents (Section D); Piracy and Counterfeiting on E-Commerce Platforms (Section E); Geographical Indications (Section F); Manufacture and Export of Pirated and Counterfeit Goods (Section G); Bad-Faith Trademarks (Section H); Judicial Enforcement and Procedure in Intellectual Property Cases (Section I); Bilateral Cooperation on Intellectual Property Protection (Section J); and Implementation (Section K).  There are many specifics enunciated in these Sections, but they have in common that almost all of them recite a provision saying:  "The United States affirms that its existing measures are consistent with its obligations in this Chapter" while setting forth specific representations and obligations for China to adhere to under these specific Sections.  In context, these provisions appear to be an agreement that China will adopt U.S. law and practices (for example, in Article 1.5(2) regarding such specifics as when to shift the burden of proof to those accused of trade secret misappropriation in the face of a quantum of evidence that trade secret misappropriation has occurred) and "prohibit the unauthorized disclosure of undisclosed information, trade secrets, or confidential business information by government personnel or third party experts or advisors in any criminal, civil, administrative, or regulatory proceedings conducted at either the central or sub-central levels of government in which such information is submitted."

    Regarding patents on pharmaceuticals, the agreement will loosen the strict application of Chinese law that has prevented applicants to provide supplemental information (i.e., not in the specification as filed) to support sufficiency of disclosure or a showing of inventive step in patent applications filed in China (which is a significant concession by China what will on its face provide patent protection for subject matter that was prior to signing the agreement unable to be patented).  China also agrees to establish patent term extensions to make up for patent prosecution and regulatory approval delays.  And the concessions in Section G regarding export of counterfeit goods may be the most significant, in view of accusations by the USTR of China's role in worldwide counterfeiting; particularly regarding counterfeit medicines, these requirements are very specific (Article 1:18(2)).

    Chapter 2 involves technology transfer issues and the importance of having this objective achieved "on voluntary, market-based terms" in contrast to "forced" technology transfer, which is "a significant concern." This section addresses situations where the U.S. has alleged China has required disclosure of technology as a quid pro quo for coming to agreement with U.S. companies.

    Chapter 3 sets forth the parties' agreement regarding trade in food and agricultural products, pledging "agricultural cooperation," although the terms of such agreements are "to be mutually agreed upon," i.e., not yet resolved.  The agreement also contains provisions wherein the China-United States Scientific Cooperation and Exchange Program continues and there are to be "exchanges and dialogues on agricultural topics."  But this chapter contains much more language regarding what the parties intend to address in future rather than firm (relatively) agreements on specific terms (and Annex 1:11 provides that "[f]or greater certainty, nothing in this Annex shall obligate either Party to expend, obligate, or transfer any funds, or to dedicate personnel or other resources to any cooperative activity").  Annex 2 of this Chapter concerns dairy products, infant formula, and inspections thereof (directed towards "meeting Chinese consumers' ever-growing needs").  Annex 3 concerns poultry (of particular concern in view of the propensity for variant strains of influenza to arise in domesticated poultry) and specifically committing the parties to sign and implement the Protocol on Cooperation on Notification and Control Procedures for Certain Significant Poultry Diseases within 30 days of when the agreement enters into force.  Annex 4 concerns beef and commits the parties to continue to implement the 2017 Protocol for importing U.S. beef into China (with the terms of this agreement prevailing if there are inconsistencies), Annex 5 live breeding cattle, Annex 6 pork, and Annex 7 meat, poultry and processed meats, significantly wherein China acknowledges USDA's Food Safety and Inspection Service (FSIS) oversight over U.S.-sourced "meat, poultry meat, and processed meat and poultry meat facilities" but permitting China to have the right to audit U.S. food safety regulatory systems in coordination with FSIS.  Annex 8 concerns electronic meat and poultry information systems to "access FSIS export certificates accompanying U.S. exports to China of meat, poultry, and meat and poultry products."  Annex 9 concerns aquatic products (albeit committing to "resume bilateral meetings of the U.S.-China Technical Working Group on Seafood" and identifying steps to for China to provide evidence regarding controls for seafood products to be imported into the U.S.).  Annex 10 concerns rice, and Annex 11 plant health (agreeing to consultations regarding a "phytosanitary protocol" for Chinese Bonsai, but excluding orchids).  Also within the scope of this annex are phytosanitary protocols for imports to the U.S. of Chinese fragrant pear, Chinese citrus, and Chinese Jujube, and importation into China of U.S. potatoes, nectarines, blueberries, Hass avocadoes, barley, and alfalfa, but agreeing phytosanitary protocols are not required for frozen fruits and vegetables.  Annex 12 concerns feed additives, premixes, compound feed, distillers' dried grains, and distillers' dried grains with solubles (mostly involving provisions that on-site audits or inspections are not required).  Annex 13 concerns pet food and non-ruminant derived animal feed, wherein China will lift its ban on U.S. pet food containing ruminant ingredients and eliminate the use of polymerase chain reaction testing on such products.  The parties also agree to have "technical discussions" in support of importing U.S. pet food into China while maintaining compliance with the 2004 Protocol on the Veterinary Health Requirements for Non-Ruminant Derived Animal Feed and Tallow to be Imported from the United States of America to the People's Republic of China.  Annex 14 involves tariff rate quotas regarding food products; Annex 15 concerns "domestic support" in China regarding China's WTO obligations; and Annex 16 relates to agricultural biotechnology, with China agreeing to "implement a transparent, predictable, efficient, science- and risk-based regulatory process for safety evaluation and authorization of products of agricultural biotechnology." Finally, Annex 17, related to food safety, regards agreement that "[t]he Parties shall not implement food safety regulations, or require actions of the other Party's regulatory authorities, that are not science- or risk-based and shall only apply such regulations and require such actions to the extent necessary to protect human life or health" (without regard to the irony of the Trump administration including these provisions into this agreement).  This chapter also contains appendices regarding food products not eligible for import from the U.S. to China.

    Chapter 4 is directed to financial services, wherein the parties evince a belief that "they have a significant opportunity for cooperation and mutual benefit in bilateral services trade."  Article 4.2 relates to banking services; Article 4.3 to credit rating services (including provisions that the U.S. "affirms it accords non-discriminatory treatment to Chinese credit rating service suppliers"); Article 4.4 for electronic payment services (including provisions that the U.S. "affirms it accords non-discriminatory treatment to Chinese electronic payment service suppliers, including UnionPay"); Article 4.5 to financial asset management services; Article 4.6 to insurance services; and Article 4.7 for securities, fund management, futures services.

    Chapter 5 is directed towards macroeconomic policies and exchange rate matters and transparency, wherein the parties pledge to "respect the other Party's autonomy in monetary policy, in accordance with its domestic law," involving "pursuing policies that strengthen underlying economic fundamentals, foster growth and transparency, and avoid unsustainable external imbalances."

    Chapter 6 is more directly aspirational regarding expanding trade, having to do with "trade and economic structural changes resulting from this Agreement and from other actions being taken by China to open up its economy and improve its trade regime should lead to improved trade flows, including significant increases in exports of goods and services to China by the United States and other countries."  China agrees to import no less than $200 billion of U.S. goods between January 1, 2020 and December 31, 2021, with more specific quotas (because that is what they appear to be) of particular goods set out in Article 6.2 (including manufactured goods, agricultural goods, energy products and services); the agreement contains an extensive table of the types of goods and services encompassed by these provisions of the agreement.

    Chapter 7 sets forth dispute resolution provisions in an "arrangement" wherein is provided a Trade Framework Group for setting forth the mechanisms for implementing the agreement (under Article 7.2.1, entitled "High Level Engagement"), to be led by the U.S. Trade Representative and "a designated Vice Premier" of the PRC.  Also provided are "macroeconomic meetings" led by the U.S Secretary of the Treasury and the designated Vice Premier of the PRC.  For "daily work, the agreement provides a Bilateral Evaluation and Dispute Resolution Office for each country.  The agreement permits each country to request information from the other (Article 7.3) and Article 7.4 sets forth mechanisms for dispute resolution (specifics for the "working procedures" of the Group are set forth in Annex 7-A).

    The final Chapter 8 involves amendments, entry into force and termination provisions, and for further negotiations.

    As mentioned above, one interesting feature of the agreement is that many of the provisions setting forth standards for protection of party rights contain the affirmative statement (requirement to requirement) that "[t]he United States affirms that existing U.S. measures afford treatment equivalent to that provided for in this Article," indicating that the negotiators conceded to adopt U.S. standards for intellectual property protection and other matters falling within the scope of the agreement.  Indeed, it is difficult to ascertain any concessions made by the U.S. for obtaining China's approval of these terms.  There is an aphorism that if a deal seems to good to be true then perhaps it isn't (true, that is).  It is contrary to this administration's puffery that the U.S. might not get the better part of any agreement it enters, and when making arrangements with economically weaker partners that may tend to be true because the odds tend to be stacked in our country's favor.  But in view of China's strengths it might be foolish to think that the Chinese will be as accommodating as the Trump Administration would prefer them to be, and agreements inconsistent with these realities are likely to be ephemeral.

  • CalendarJanuary 28, 2020 – Biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting (U.S. Patent and Trademark Office) – Alexandria, VA

    January 28, 2020 – "Obtaining Patent Protection for Polymorphs of Drug Compounds" (J A Kemp) – 3:30 to 4:30 pm (GMT)

    January 30, 2020 – "American Axle: Does Patent Subject Matter Eligibility Depend on Enablement?" (Fitch Even) – 12:00 to 1:00 pm (ET)

    February 4, 2020 – "Leveraging Active Voice in Patent Claims" (Practising Law Institute) – 1:00 to 2:00 pm (EST)

    February 13, 2020 – "Litigating Civil and Criminal Trade Secret Cases: Trends, Best Practices, and Lessons Learned" (Practising Law Institute) – 1:00 to 2:00 pm (EST)

    February 18, 2020 – "Patent Eligibility and Section 101 Update" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

  • MBHB Logo 2McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "Patent Eligibility and Section 101 Update" on February 18, 2020 from 10:00 am to 11:15 am (CT).  In this presentation, MBHB attorney and Patent Docs author Michael Borella will provide an update on all fronts, and synthesize disparate threads into a cohesive set of best practices for handling 101 issues in patent prosecution in particular.  The webinar will focus on software, business methods, and other technologies that relate to the "abstract idea" exception, though the issues and recommendations do cross over into the life sciences fields as well.  Topics to be cobered will include:

    • Introduction and background
    • Current 101 framework
    • Case law update (the good, the bad, and the even worse)
    • The Patent Office's updated guidance — analysis and applications
    • Congressional (in)actionBest practices in light of the above
    • Best practices in light of the above

    While there is no fee to participate, attendees must register in advance.  Those wishing to register can do so here.  CLE credit is pending for the states of California, Illinois, New Jersey, New York, North Carolina, and Virginia.

  • PLI #1Practising Law Institute (PLI) will be offering a one-hour webcast on "Leveraging Active Voice in Patent Claims" on February 4, 2020 beginning at 1:00 pm (EST).  Jason M. Perilla of Thomas | Horstemeyer, LLP will introduce and explore the use of active voice in drafting patent claims and discuss:

    • How to organize and prioritize the important aspects of an invention before drafting patent claims;
    • How to identify the "actors" of an invention, particularly in the context of computer-environment-related inventions;
    • Avoiding the use of "wherein" clauses and other claim limitations that are unhinged from a particular actor and, perhaps, the invention itself; and
    • Leveraging active voice to help avoid "abstract idea" rejections under § 101.

    The registration fee for this webcast is $299.  Those interested in registering for the webcast, can do so here.

  • PLI #1Practising Law Institute (PLI) will be offering a one-hour webcast on "Litigating Civil and Criminal Trade Secret Cases: Trends, Best Practices, and Lessons Learned" on February 13, 2020 beginning at 1:00 pm (EST).  Jeffrey M. Fisher and Janice W. Reicher of Farella Braun + Martel LLP will provide an overview of:

    • Trends in trade secret litigation, both civil and criminal, and best practices in litigating these cases;
    • Differences in the trade secret law and considerations in civil vs. criminal cases;
    • How to protect your valuable intellectual property, including key issues relating to litigation involving non-disclosure agreements and employment agreements;
    • Lessons learned from recent civil trade secret jury trials, including Huawei v. CNEX and Bladeroom v. Facebook and Emerson; and
    •
    Certain high profile criminal trade secret cases including US v. Levandowski and US v. Huawei.

    The registration fee for this webcast is $299.  Those interested in registering for the webcast, can do so here.

  • By Dan Feigelson* —

    IL PTOMany patent practitioners will never have need to file a patent application in Israel, a country of nine million people that's geographically smaller than New Jersey.  But if you're one of those practitioners who does file in Israel from time to time — and I suspect that readers of Patent Docs file in Israel at a higher rate than the general practitioner population — you'll be pleased to know that the Israel PTO (ILPTO) recently proposed a change in patent examination practice that portends relief for beleaguered applicants:  the ILPTO plans to tighten the criteria for rejecting claims of an applicant's application for "overlap" with the claims of another of the applicant's applications (or granted patents).  The upshot will be that the ILPTO will no longer make such rejections in the case of divisional applications on the basis of the claims of an ancestor application.

    By way of background, section 2 of the Israel patent statute says that an applicant may obtain a patent for his invention.  Like 35 U.S.C. § 101, Israel section 2 has been interpreted to mean you can get one patent per invention.  So you can't get two claims of the same scope in two different patents.

    Where the difficulty has arisen is when the claims of an applicant's separate applications are of different, but nevertheless overlapping, scope.  To illustrate, suppose a parent application claims a single chemical compound, and a related child application claims a genus of compounds that encompasses that compound.  In the U.S., such a situation would give rise not to a statutory double-patenting rejection under § 101 (since the claims are not of identical scope), but to an obviousness-type double-patent rejection.  And the response in the U.S. would be to file a terminal disclaimer, which would achieve two things:  it would ensure that the two patents expire at the same time (generally not an issue since June 1995, when the U.S. switched to a 20-years-from-earliest-filing-date-system); and it would ensure that the patents must be co-owned for the later-issuing patent to be enforceable.

    In Israel, until now, that same set of facts would also result in the ILPTO rejecting the child claim(s), and the assertion made by the ILPTO would be that the child claim(s) "overlap" with the parent claim(s).  The problem is that whereas in the U.S., it's recognized that obviousness-type double-patenting is a judicially created-doctrine, in Israel, there is no comparable case law.  Thus, despite the fact that the statute seems to be clear that only identical claims in two of an applicant's applications are forbidden (section 13 says that it's the claims that define the invention, which would seem to mean that as long as the claims aren't of identical scope, section 2 doesn't apply), the ILPTO has for years taken the view that section 2 precludes the allowance of such "overlapping" claims.  In other words, the ILPTO conflates statutory double-patenting with obviousness-type double-patenting.  As one might expect, this practice has not been without criticism, see, e.g., here, here, here, and here.

    Although it has been proposed that the ILPTO adopt a terminal disclaimer practice like that in the U.S., until now the only way for an applicant to overcome an "overlap" rejection has been to either remove the offending matter from the claims of one of the applications (either by deleting one or more positive recitations from the offending claim(s), or introducing one or more provisos), or to show that the offending claims constitute a non-obvious selection over the earlier claims.  (The latter option shows the paucity of the logical underpinnings of the ILPTO's position:  if the statute requires that there be no overlap between the scope of the claims in an applicant's different applications, a showing of non-obviousness doesn't obviate the double-patenting problem.)

    The ILPTO's approach to "overlap" has been vexing for pharma and biotech applicants in Israel.  For example, if an examiner is willing to allow claims of a narrower scope than the applicant believes it is entitled, in the U.S. the applicant will take the allowance of the narrower claims now, and fight for the broader claims in a continuation, knowing that it may be necessary to file terminal disclaimer to get around the claims of the parent case.  But in Israel, taking the narrower claims in the parent case might presage an "overlap" rejection, which at best would necessitate figuring out a way to eliminate that "overlap," a task that sometimes requires a significant investment of time, and in some cases might not be easily or satisfactorily accomplished.

    The ILPTO's obsession with overlap hasn't been a headache just for applicants and their patent counsel.  It's also been a source of wasted examiner time, as examiners have been instructed to conduct search-and-destroy mission against "overlap" as part of their job.

    It was apparently this last aspect of the practice that finally got the attention of the powers-that-be at the Israel PTO.  In a notice published on December 29, 2019, regarding proposed revisions to the Examination Guidelines (the ILPTO's equivalent of the MPEP), the ILPTO proposes to forego raising "overlap" rejections in cases of patent applications, or a patent application and a patent, which are (a) owned by the same entity and (b) have the same filing date, provided that the two documents do not contain claims of "literally or substantively" identical scope.  This means that the ILPTO plans to stop raising "overlap" rejections in cases of parent and divisional applications, as long as the claims are of different scopes.

    The specific proposed amended wording of the Examination Guidelines regarding "overlap" (in Hebrew) can be found here beginning at page 30.  The ILPTO has asked for comments on the proposed revisions to the Guidelines, to be sent to Patentim_Bhina@justice.gov.il by January 29, 2020.  It is expected that this proposal will be formally implemented soon thereafter; rumor has it that the ILPTO is in fact already implementing this change.

    * Daniel Feigelson is a patent practitioner based in Israel, who from time to time writes about U.S. and Israel patent issues at www.iliplaw.com.

  • By Donald Zuhn –-

    World Health OrganizationLast week, the World Health Organization (WHO) issued two reports suggesting that declining private investment and lack of innovation in the development of new antibiotics is undermining efforts to combat drug-resistant infections.  The WHO reports address fifty antibiotics (and ten antibacterial biologics) that are currently in clinical and preclinical development (see "Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline" and "Antibacterial agents in preclinical development").  However, the WHO reports indicate that these compounds "bring little benefit over existing treatments and very few target the most critical resistant bacteria (Gram-negative bacteria)."

    The Director-General of WHO, Dr. Tedros Adhanom Ghebreyesus, noted that "[n]ever has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent," adding that "[n]umerous initiatives are underway to reduce resistance, but we also need countries and the pharmaceutical industry to step up and contribute with sustainable funding and innovative new medicines."  WHO also pointed out that research and development for antibiotics is primarily driven by small- or medium-sized enterprises, and that large pharmaceutical companies continue to exit the field of antibiotic research.

    With respect to its review of the clinical development of antibiotic agents, WHO noted that of the fifty antibiotics in the pipeline, 32 target pathogens that appeared on WHO's 2017 list of priority pathogens, but that the majority of antibiotics in clinical development have limited benefits when compared to existing antibiotics.  In addition, only two of the fifty antibiotics are active against multi-drug resistant Gram-negative bacteria, which WHO indicated are spreading rapidly and require urgent solutions.  The WHO report also highlights a "worrying gap in activity" against NDM-1 (New Delhi metallo-beta-lactamase 1), an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics.  According to the WHO report, there are only three antibiotics in the pipeline that can be used to treat resistant bacteria expressing NDM-1 (often referred to as "superbugs").  As for its review of the preclinical development of antibiotic agents, the WHO report suggests that an optimistic scenario is for the first two to five products to become available in about 10 years.

    WHO Assistant Director-General for Antimicrobial Resistance, Hanan Balkhy, stated that "[i]t's important to focus public and private investment on the development of treatments that are effective against the highly resistant bacteria because we are running out of options."  WHO also noted that with respect to antibiotic research and development, WHO and the Drugs for Neglected Diseases Initiative (DNDi) have established the Global Antibiotic Research and Development Partnership (GARDP), a non-profit research and development organization that is working with more than fifty public and private sector partners in twenty countries to accelerate the development of new and improved antibiotics to tackle drug-resistant infections.  GARDP's goal is to deliver five new treatments by 2025.

  • By Donald Zuhn –-

    Federal Circuit SealLast week, the Federal Circuit issued a per curiam Order in BioDelivery Sciences International, Inc. v. Aquestive Therapeutics, Inc., denying a petition for a panel rehearing or rehearing en banc filed by Appellant BioDelivery Sciences International, Inc.  Judge Newman dissented from the denial of the petition for rehearing en banc.

    The dispute between the parties arose when BioDelivery sought inter partes review of claims 1, 4, 6–9, 11, 12, 26, 27, 32, 38, 44, 51, 58, 65, 72, 82, 109, and 125–127 of U.S. Patent No. 8,765,167, citing seven prior art grounds of anticipation or obviousness.  The U.S. Patent and Trademark Office Patent Trial and Appeal Board instituted the IPR on most, but not all, of the challenged claims, and on one of the grounds.  The PTAB ultimately issued a Final Written Decision finding claims 1, 4, 11, 12, 26, 27, 44, 51, 58, 65, 72, 82, and 125–127 of the '167 patent to be patentable.

    BioDelivery appealed to the Federal Circuit, which received briefing and argument before the Supreme Court issued its decision in SAS Institute Inc. v. Iancu.  On BioDelivery's motion, the Federal Circuit directed the PTAB "to implement the Court's decision in SAS."  In response, the PTAB "modif[ied its] Decision to Institute and instead deny the Petition in its entirety, thereby terminating [the] proceeding," and in particular, "ORDERED that Petitioner's request for inter partes review of claims 1, 4, 6–9, 11, 12, 26, 27, 32, 38, 44, 51, 58, 65, 72, 82, 125–127 of the '167 patent is denied and no inter partes review is instituted."

    Judge Newman, dissenting from the denial of the petition for rehearing en banc, stated that:  "I write because of the significance of the balance of agency and judicial authority, and the rules of procedural law in the administrative state."  Noting that the Supreme Court in SAS held that 35 U.S.C. § 318(a) requires that in an inter partes review the PTAB must decide all of the claims and grounds challenged in the petition, Judge Newman indicated that "the PTAB had not met this requirement for these cases [the appeal consolidated three separate PTAB decisions]."  In particular, Judge Newman noted that "[t]he PTAB did not comply with the Remand Order, stating that it would be inefficient and expensive to include the additional claims and grounds," with the PTAB explaining in its Decision on Remand that "[b]ecause the overwhelming majority of unpatentability grounds presented by Petitioner fail to meet the standard for institution of inter partes review, we find that instituting trial as to those grounds at this time is neither in the interest of the efficient administration of the Office, nor in the interest of securing an inexpensive resolution of this proceeding."  In her dissent, Judge Newman writes that:

    [M]y colleagues hold that the PTAB is not required to comply with the court's Remand Order, and further hold that this non-compliance is not reviewable.  This action raises critical issues of agency authority, judicial responsibility, and the constitutional plan.

    Judge Newman declares that "[m]y concern is with the PTAB's position that it need not follow the court's Remand Order, for reasons of efficiency and expense," adding that "[s]uch agency authority cannot be discerned in the America Invents Act, and contravenes decades of constitutional jurisprudence."  Citing Banks v. United States, 741 F.3d 1268, 1276 (Fed. Cir. 2014) (quoting Briggs v. Pa. R. Co., 334 U.S. 304, 306 (1948)), Judge Newman notes that agency action is bound by the mandate rule, which:

    [D]ictates that 'an inferior court has no power or authority to deviate from the mandate issued by an appellate court.'  Once a question has been considered and decided by an appellate court, the issue may not be reconsidered at any subsequent stage of the litigation, save on appeal.

    Judge Newman also observes that "[t]he legislative record contains no contemplation of a PTAB procedure whereby, after full PTAB trial and decision and appeal to the Federal Circuit, the PTAB could annul the appeal and remove the entire action and decisions and procedure from history, insulated from review."  As a result, Judge Newman found the PTAB's action in this case to be "seriously flawed."  According to Judge Newman, "[t]he PTAB's refusal to comply with our Remand Order to implement the Supreme Court's ruling warrants en banc attention," and she therefore dissented from the denial of the petition for rehearing en banc.

    BioDelivery Sciences International, Inc. v. Aquestive Therapeutics, Inc. (Fed. Cir. 2020)
    Per curiam
    Before Chief Judge Prost and Circuit Judges Newman, Lourie, Dyk, Moore, O'Malley, Reyna, Wallach, Taranto, Chen, and Hughes; dissenting opinion by Circuit Judge Newman

  • CalendarJanuary 22, 2020 – "Top Patent Law Stories of 2019" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    January 22, 2020 – "Pot Topic: IP Issues for the New Recreational Weed Industry in Illinois" (The Intellectual Property Law Association of Chicago Young Members' Committee) – 5:30 to 9:00 pm (CT), Chicago, IL

    January 23, 2020 – "PTAB Year in Review" (Foley & Lardner) – 1:00 to 2:00 pm (CT)

    January 23, 2020 – "Text and Data Mining Laws: International Developments" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    January 28, 2020 – Biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting (U.S. Patent and Trademark Office) – Alexandria, VA

    January 28, 2020 – "Obtaining Patent Protection for Polymorphs of Drug Compounds" (J A Kemp) – 3:30 to 4:30 pm (GMT)

    January 30, 2020 – "American Axle: Does Patent Subject Matter Eligibility Depend on Enablement?" (Fitch Even) – 12:00 to 1:00 pm (ET)

  • USPTO Building FacadeThe U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on January 28, 2020 at the USPTO Headquarters in Alexandria, VA.  The agenda for the meeting is as follows:

    • Welcoming and Opening Remarks (10:30 – 10:40 am ET) — Gary Jones and Andrew Wang, Directors, and Karl Skowronek, Director (Acting), TC1600, USPTO

    • Restriction practice (10:40 – 11:20 am) — Janet Andres, SPE, TC1600, USPTO

    • Orange Book and biologic patent study 11:20 – 12:00 pm) — Michelle Ankenbrand, Lead Administrative Patent Judge, and Jason Repko, Administrative Patent Judge, PTAB, USPTO

    • Lunch/Networking (12:00 – 1:00 pm)

    • Patent term adjustment (1:00 – 1:50 pm) — Kery Fries, Senior Legal Advisor, OPLA, USPTO

    • Satisfying the written description requirement for living inventions (1:50 – 2:50 pm) — Bethany Reid Roahrig, Patent Agent, Setter Roche LLP

    • Break (2:50 – 3:00 pm)

    • Subject matter eligibility (101) update (3:00 – 4:30 pm) – Zachariah Lucas, QAS, TC1600, USPTO

    • Closing Remarks (4:30 – 4:40 pm) – Directors, TC1600, USPTO

    Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.